Summary of effects for transition to psychosis
| Comparison | Time point (months of treatment) | No (%) of trials in analysis | No (%) of participants in analysis | Risk ratio (95% CI), random effects | Heterogeneity (I2 (%), χ2 (P)) | Quality of evidence (GRADE) |
|---|---|---|---|---|---|---|
| CBT v supportive counseling23-25, 28, 29 | 0-6 | 4 (80) | 591 (88) | 0.62 (0.29 to 1.31) | 17, 3.6 (P=0.31) | Low*‡ |
| 6-12 | 5 (100) | 645 (71) | 0.54 (0.34 to 0.86) | 0, 2.51 (P=0.64) =0.P2) | Moderate* | |
| 12+ | 4 (80) | 570 (85) | 0.63 (0.40 to 0.99) | 0, 2.50(P=0.48) | Low*‡ | |
| CBT and risperidone v supportive counselling24, 30 | 0-6 | 2 (100) | 130 (100) | 0.35 (0.13 to 0.95) | 0, 0.59 (P=0.44) | Very low*ठ|
| 6-12 | 2 (100) | 130 (100) | 0.63 (0.33 to 1.21) | 0, 0.25 (P=0.61) | Very low*ठ| |
| 12+ | 1 (50) | 41 (32) | 0.59 (0.34 to 1.04) | NA | Very low*ठ| |
| Integrated psychotherapy v supportive counselling37 | 6-12 | 1 (100) | 125 (100) | 0.19 (0.04 to 0.81) | NA | Very low*ঠ|
| 12+ | 1 (100) | 125 (100) | 0.32 (0.11 to 0.92) | NA | Very low*ঠ| |
| Integrated psychotherapy v standard care35 | 6-12 | 1 (100) | 67 (85) | 0.24 (0.07 to 0.81) | NA | Low*‡ |
| 12+ | 1 (100) | 65 (82) | 0.52 (0.26 to 1.02) | NA | Low*‡ | |
| CBT and risperidone v CBT and placebo24 | 0-6 | 1 (100) | 87 (100) | 1.02 (0.15 to 6.94) | NA | Very low*ठ|
| 6-12 | 1 (100) | 87 (100) | 1.02 (0.39 to 2.67) | NA | Very low*ठ| |
| Olanzapine v placebo27 | 6-12 | 1 (100) | 60 (100) | 0.43 (0.17 to 1.08) | NA | Very low*ठ|
| Omega 3 fatty acids v placebo26 | 0-6 | 1 (100) | 76 (94) | 0.13 (0.02 to 0.95) | NA | Low*§ |
| 6-12 | 1 (100) | 81 (100) | 0.18 (0.04 to 0.75) | NA | Low*§ |
NA=not applicable; NBI=needs based intervention.
*Reason for downgrading: imprecision.
†Reason for downgrading: inconsistency.
‡Reason for downgrading: risk of bias.
§Reason for downgrading: risk of publication bias.
¶Reason for downgrading: indirectness.